Hilton Hotels Corporation Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $330.2 (market cap $74.18B), while Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 8.7× Hinge Health Inc. Class A Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| HLT | HNGE | |
|---|---|---|
Market Cap | $74.18B | $8.48B |
Volume | 1,295,545 | 879,799 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $105.14 |
52-Week Low | $256.96 | $31.17 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $87.19B | $8.10B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $328.12, up 0.18% on the day, with strong technical momentum as the stock approaches resistance near $330. The company demonstrates solid fundamental performance with revenue growth from $12.04B in 2025 to projected $12.5B in 2026, consistently beating earnings expectations in recent quarters. Analyst sentiment remains bullish with 57% buy ratings and a $350 consensus price target, supported by institutional accumulation and positive travel industry trends.
HLT presents a compelling investment case with strong earnings momentum and global portfolio expansion, though elevated valuation metrics (P/E 48.4) and rising debt levels warrant caution. The stock's proximity to technical resistance and overbought RSI readings suggest potential near-term consolidation before further upside toward analyst targets. Key risks include macroeconomic sensitivity and competitive pressures in the hospitality sector.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →